MINNEAPOLIS–(BUSINESS WIRE)–Aug 3, 2026–
Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR) is pleased to announce the launch of Imricor Cardiovascular, a new vertical that expands the interventional MR (iMR) market for Imricor alongside its electrophysiology and ablation business. Following recent FDA clearances for NorthStar ® and the Vision-MR ® Diagnostic Catheter, Imricor Cardiovascular gives U.S. hospitals an opportunity to establish early leadership in radiation-free cardiac catheterization by performing these procedures in an iMR lab utilizing the superior imaging power of magnetic resonance (MR).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803726114/en/…